Angelidis Panagiotis, Karagiannis Dimitrios, Crump Elizabeth M
Laboratory of Ichthyology and Ichthyopathology, Aristotle University of Thessaloniki, PO Box 395, 54124 Thessaloniki, Greece.
Dis Aquat Organ. 2006 Jul 11;71(1):19-24. doi: 10.3354/dao071019.
The efficacy of a commercial bivalent Listonella anguillarum (serotype 01 and 02) vaccine (MICROViB, Microtek International) was tested on prime- and booster-immersion vaccinated sea bass Dicentrarchus labrax juveniles. We carried out 2 challenge tests on the prime-vaccinated fish, 50 and 90 d after initial vaccination. A second group of fish received a booster vaccination 60 d after the prime vaccination, and were tested with a single challenge 30 d later. Relative percent survival (RPS) was 92 and 84% (both p < 0.01) among the prime-vaccinated fish on the first and second challenges, respectively. The RPS of the booster-vaccinated sea bass was 100% (p < 0.01). Antibody titres were tested only among 10 prime-vaccinated and 10 unvaccinated (control) sea bass, 60 d post-immunisation, and were found to rise to 1/32 in the vaccinated fish. Our results demonstrate that MICROViB immersion vaccine can effectively protect juvenile sea bass from L. anguillarum infection.
一种商业化的双价鳗弧菌（血清型01和02）疫苗（MICROViB，Microtek International）对初免和加强免疫浸泡接种的欧洲鲈幼鱼的效力进行了测试。我们对初免鱼在初次接种后50天和90天进行了2次攻毒试验。第二组鱼在初免后60天接受加强免疫，30天后进行单次攻毒试验。初次接种的鱼在第一次和第二次攻毒试验中的相对存活率（RPS）分别为92%和84%（均p<0.01）。加强免疫的欧洲鲈的RPS为100%（p<0.01）。仅在免疫后60天对10条初免和10条未免疫（对照）的欧洲鲈检测了抗体滴度，发现接种鱼的抗体滴度升至1/32。我们的结果表明，MICROViB浸泡疫苗可有效保护欧洲鲈幼鱼免受鳗弧菌感染。
